| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 7,000 | 3,200 | ||
| General and administrative | 3,040 | 4,016 | ||
| Total operating expenses | 10,040 | 7,216 | ||
| Loss from operations | -10,040 | -7,216 | ||
| Interest income | 687 | 754 | ||
| Net loss attributable to common stockholders | -9,353 | -6,462 | ||
| Unrealized gain (loss) on investments | 39 | -23 | ||
| Comprehensive loss | -9,314 | -6,485 | ||
| Earnings per share, basic, total | -0.31 | -0.21 | ||
| Earnings per share, diluted, total | -0.31 | -0.21 | ||
| Weighted average number of shares outstanding, basic, total | 30,276,230 | 30,172,328 | ||
| Weighted average number of shares outstanding, diluted, total | 30,276,230 | 30,172,328 | ||
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)